JP7896251B2 - 骨関節炎痛の治療のためのｌｉｎｋ－ｔｓｇ６の使用 - Google Patents

骨関節炎痛の治療のためのｌｉｎｋ－ｔｓｇ６の使用

Info

Publication number
JP7896251B2
JP7896251B2 JP2023543339A JP2023543339A JP7896251B2 JP 7896251 B2 JP7896251 B2 JP 7896251B2 JP 2023543339 A JP2023543339 A JP 2023543339A JP 2023543339 A JP2023543339 A JP 2023543339A JP 7896251 B2 JP7896251 B2 JP 7896251B2
Authority
JP
Japan
Prior art keywords
pain
link
tsg6
osteoarthritis
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023543339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504683A (ja
JP2024504683A5 (enExample
Inventor
デイ，アンソニー
ミルナー，キャロライン
Original Assignee
リンク・バイオロジックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リンク・バイオロジックス・リミテッド filed Critical リンク・バイオロジックス・リミテッド
Publication of JP2024504683A publication Critical patent/JP2024504683A/ja
Publication of JP2024504683A5 publication Critical patent/JP2024504683A5/ja
Application granted granted Critical
Publication of JP7896251B2 publication Critical patent/JP7896251B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023543339A 2021-01-20 2022-01-19 骨関節炎痛の治療のためのｌｉｎｋ－ｔｓｇ６の使用 Active JP7896251B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100761.2A GB202100761D0 (en) 2021-01-20 2021-01-20 Treatment of osteoarthritic pain
GB2100761.2 2021-01-20
PCT/EP2022/051101 WO2022157181A1 (en) 2021-01-20 2022-01-19 Use of link-tsg6 for the treatment of osteoarthritic pain

Publications (3)

Publication Number Publication Date
JP2024504683A JP2024504683A (ja) 2024-02-01
JP2024504683A5 JP2024504683A5 (enExample) 2025-01-28
JP7896251B2 true JP7896251B2 (ja) 2026-07-29

Family

ID=74679050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543339A Active JP7896251B2 (ja) 2021-01-20 2022-01-19 骨関節炎痛の治療のためのｌｉｎｋ－ｔｓｇ６の使用

Country Status (8)

Country Link
US (1) US20250121028A1 (enExample)
EP (1) EP4281098A1 (enExample)
JP (1) JP7896251B2 (enExample)
KR (1) KR20230142502A (enExample)
CN (1) CN116744958A (enExample)
CA (1) CA3204755A1 (enExample)
GB (1) GB202100761D0 (enExample)
WO (1) WO2022157181A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910645D0 (en) 2019-07-25 2019-09-11 Univ Manchester Treatment for dry eye disease
GB202416087D0 (en) 2024-10-31 2024-12-18 Link Biologics Treatment of ocular disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150057229A1 (en) 2006-03-06 2015-02-26 The University Of Manchester Method of treating bone disorders using tsg-6

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104703146B (zh) 2013-12-09 2019-03-08 腾讯科技（深圳）有限公司 信息推送方法、客户端及系统

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150057229A1 (en) 2006-03-06 2015-02-26 The University Of Manchester Method of treating bone disorders using tsg-6

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAY AJ, et al.，A NOVEL CHONDROPROTECTIVE PROPERTY OF TSG-6 HAS THERAPEUTIC POTENTIAL FOR OA，Osteoarthritis and Cartilage，2016年，Vol.24, Article No.21，pp.S19-S20
Mar. Drugs，2021年01月17日，Vol.19, 39，pp.1-21，https://doi.org/10.3390/md19010039
Rheumatology，2011年，Vol.50，pp.261-270，doi:10.1093/rheumatology/keq285
三木健司ほか，変形性関節症患者におけるタネズマブ皮下注射の有効性の発現時期とその効果の持続性，日整会誌（J. Jpn. Orthop. Assoc.），2020年，Vol.94, No.8，p.S1843 2-7-24

Also Published As

Publication number Publication date
EP4281098A1 (en) 2023-11-29
KR20230142502A (ko) 2023-10-11
GB202100761D0 (en) 2021-03-03
CA3204755A1 (en) 2022-07-28
US20250121028A1 (en) 2025-04-17
CN116744958A (zh) 2023-09-12
JP2024504683A (ja) 2024-02-01
WO2022157181A1 (en) 2022-07-28

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260605

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260625

R150 Certificate of patent or registration of utility model

Ref document number: 7896251

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150